Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1035
Name aggressive NK-cell leukemia
Definition A leukemia that is characterized by the systemic proliferation of NK cells closely associated with Epstein-Barr virus and that is located_in the peripheral blood, bone marrow, liver, and spleen.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia aggressive NK-cell leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT03203369 Phase I UCART123 Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123) Terminated USA 0
NCT03598998 Phase Ib/II Pembrolizumab + Pralatrexate Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas Active, not recruiting USA 0
NCT03719105 Phase I Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Recruiting USA 0
NCT04109482 Phase Ib/II Cyclophosphamide + Decitabine + Fludarabine + MB-102 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. Terminated USA 0
NCT04984837 Phase II Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin Study of Lacutamab in Peripheral T-cell Lymphoma Recruiting FRA | ESP | DEU | BEL 0
NCT05010005 Phase I Duvelisib + Ruxolitinib A Study of Ruxolitinib and Duvelisib in People With Lymphoma Active, not recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Active, not recruiting USA 0